ReShape Lifesciences (OTCMKTS:RSLSD) & Biosig Technologies (NASDAQ:STEX) Critical Analysis

Biosig Technologies (NASDAQ:STEX) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Biosig Technologies and ReShape Lifesciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
ReShape Lifesciences	0	0	0	0	0.00

Given ReShape Lifesciences’ higher possible upside, analysts plainly believe ReShape Lifesciences is more favorable than Biosig Technologies.

Profitability

This table compares Biosig Technologies and ReShape Lifesciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
ReShape Lifesciences	-668.58%	-163.22%	-52.10%

Institutional and Insider Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Biosig Technologies and ReShape Lifesciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$13,000.00	16,616.09	-$10.33 million	($1.35)	-0.90
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A

Biosig Technologies has higher earnings, but lower revenue than ReShape Lifesciences.

Risk & Volatility

Biosig Technologies has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.

Summary

Biosig Technologies beats ReShape Lifesciences on 6 of the 10 factors compared between the two stocks.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.